Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 1
1974 1
1975 2
1978 2
1980 2
1981 1
1982 3
1985 1
1986 2
1989 1
1992 1
1993 2
1997 1
1999 1
2002 3
2003 4
2004 1
2005 2
2006 2
2007 1
2008 2
2009 1
2011 1
2013 1
2014 5
2015 5
2016 3
2019 1
2020 5
2021 1
2022 4
2023 5
2024 5
2025 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

73 results

Results by year

Filters applied: . Clear all
Page 1
The Lancet Commission on prostate cancer: planning for the surge in cases.
James ND, Tannock I, N'Dow J, Feng F, Gillessen S, Ali SA, Trujillo B, Al-Lazikani B, Attard G, Bray F, Compérat E, Eeles R, Fatiregun O, Grist E, Halabi S, Haran Á, Herchenhorn D, Hofman MS, Jalloh M, Loeb S, MacNair A, Mahal B, Mendes L, Moghul M, Moore C, Morgans A, Morris M, Murphy D, Murthy V, Nguyen PL, Padhani A, Parker C, Rush H, Sculpher M, Soule H, Sydes MR, Tilki D, Tunariu N, Villanti P, Xie LP. James ND, et al. Among authors: grist e. Lancet. 2024 Apr 27;403(10437):1683-1722. doi: 10.1016/S0140-6736(24)00651-2. Epub 2024 Apr 4. Lancet. 2024. PMID: 38583453 Free PMC article. Review.
Tumor transcriptome-wide expression classifiers predict treatment sensitivity in advanced prostate cancers.
Grist E, Dutey-Magni P, Parry MA, Mendes L, Sachdeva A, Proudfoot JA, Hamid AA, Ismail M, Howlett S, Friedrich S, DePaula Oliveira L, Murphy L, Brawley C, Dairo O, Lall S, Liu Y, Wetterskog D, Wingate A, Nowakowska K, Zakka L, Amos CL, Atako NB, Wang V, Rush HL, Jones RJ, Leung H, Cross WR, Gillessen S, Parker CC, Marafioti T, Urbanucci A, Fittall M, Schaeffer EM, Spratt DE, Waugh D, Powles T, Sydes MR, Feng FY, Berney DM, Parmar MKB, Clarke NW, Davicioni E, Lotan TL, Sweeney CJ, Brown LC, James ND, Attard G. Grist E, et al. Cell. 2025 Oct 2;188(20):5717-5734.e10. doi: 10.1016/j.cell.2025.07.042. Epub 2025 Aug 26. Cell. 2025. PMID: 40865526 Free article.
Copy number architectures define treatment-mediated selection of lethal prostate cancer clones.
Hasan AMM, Cremaschi P, Wetterskog D, Jayaram A, Wong SQ, Williams S, Pasam A, Trigos A, Trujillo B, Grist E, Friedrich S, Vainauskas O, Parry M, Ismail M, Devlies W, Wingate A, Linch M, Naceur-Lombardelli C; PEACE consortium; Swanton C, Jamal-Hanjani M, Lise S, Sandhu S, Attard G. Hasan AMM, et al. Among authors: grist e. Nat Commun. 2023 Aug 10;14(1):4823. doi: 10.1038/s41467-023-40315-9. Nat Commun. 2023. PMID: 37563129 Free PMC article.
Clinical testing of transcriptome-wide expression profiles in high-risk localized and metastatic prostate cancer starting androgen deprivation therapy: an ancillary study of the STAMPEDE abiraterone Phase 3 trial.
Parry MA, Grist E, Mendes L, Dutey-Magni P, Sachdeva A, Brawley C, Murphy L, Proudfoot J, Lall S, Liu Y, Friedrich S, Ismail M, Hoyle A, Ali A, Haran A, Wingate A, Zakka L, Wetterskog D, Amos CL, Atako NB, Wang V, Rush HL, Jones RJ, Leung H, Cross WR, Gillessen S, Parker CC, Chowdhury S; STAMPEDE collaborators; Lotan T, Marafioti T, Urbanucci A, Schaeffer EM, Spratt DE, Waugh D, Powles T, Berney DM, Sydes MR, Parmar MKB, Hamid AA, Feng FY, Sweeney CJ, Davicioni E, Clarke NW, James ND, Brown LC, Attard G. Parry MA, et al. Among authors: grist e. Res Sq [Preprint]. 2023 Feb 8:rs.3.rs-2488586. doi: 10.21203/rs.3.rs-2488586/v1. Res Sq. 2023. PMID: 36798177 Free PMC article. Preprint.
Plasma AR Alterations and Timing of Intensified Hormone Treatment for Prostate Cancer: the STAMPEDE Phase 3 Randomized Clinical Trial.
Leone G, Orlando F, Dutey-Magni P, Vainauskas O, Grist E, Ciani Y, Lall S, Thakali S, Wingate A, Wetterskog D, Sachdeva A, Sydes MR, McPhail N, Sreenivasan T, O'Sullivan JM, Clarke NW, Parmar MKB, Brown LC, James ND, Demichelis F, Attard G; STAMPEDE collaborators. Leone G, et al. Among authors: grist e. JAMA Oncol. 2025 Feb 27;11(4):426-9. doi: 10.1001/jamaoncol.2024.7051. Online ahead of print. JAMA Oncol. 2025. PMID: 40014335
External validation of a digital pathology-based multimodal artificial intelligence-derived prognostic model in patients with advanced prostate cancer starting long-term androgen deprivation therapy: a post-hoc ancillary biomarker study of four phase 3 randomised controlled trials of the STAMPEDE platform protocol.
Parker CTA, Mendes L, Liu VYT, Grist E, Joun S, Yamashita R, Mitani A, Chen E, Parry MA, Sachdeva A, Murphy L, Huang HC, Griffin J, van der Wal D, Todorovic T, Lall S, Santos Vidal S, Goncalves M, Thakali S, Wingate A, Zakka L, Brown M, Wetterskog D, Amos CL, Atako NB, Jones RJ, Cross WR, Gillessen S, Parker CC; STAMPEDE collaborators; Berney DM, Tran PT, Spratt DE, Sydes MR, Parmar MKB, Clarke NW, Brown LC, Feng FY, Esteva A, James ND, Attard G. Parker CTA, et al. Among authors: grist e. Lancet Digit Health. 2025 Jul;7(7):100885. doi: 10.1016/j.landig.2025.100885. Epub 2025 Jun 3. Lancet Digit Health. 2025. PMID: 40467357 Free article. Clinical Trial.
73 results